Blue Shield of California's Innovative Move to Cut Humira Costs
Blue Shield's Strategic Initiative
In an unprecedented move, Blue Shield of California is bypassing traditional pharmacy benefit managers (PBMs) to implement a substantial price reduction for Humira. This effort marks a significant shift in healthcare pricing strategies.
Why is this Important?
- Effective date of January 1, 2025
- Members using Fresenius Kabi's adalimumab-aacf will incur no out-of-pocket costs
- Expected reduction of drug costs by 90%
This strategy aims to enhance medication accessibility and affordability, significantly benefiting patients who rely on Humira.
Disclaimer: The information provided on this site is for informational purposes only and is not intended as medical advice. We are not responsible for any actions taken based on the content of this site. Always consult a qualified healthcare provider for medical advice, diagnosis, and treatment. We source our news from reputable sources and provide links to the original articles. We do not endorse or assume responsibility for the accuracy of the information contained in external sources.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.